Irritable Bowel Syndrome and Digestive Health Support Forum banner
1 - 1 of 1 Posts

0 Posts
Discussion Starter · #1 ·

Marked elevations in proinflammatory polyunsaturated fatty acid metabolites in females with irritable bowel syndrome.

J Lipid Res. 2009 Nov 11;

Authors: Clarke G, Fitzgerald P, Hennessy AA, Cassidy EM, Quigley EM, Ross P, Stanton C, Cryan JF, Dinan TG

Irritable bowel syndrome (IBS) is the most common functional gastrointestinal disorder referred to gastroenterologists. Although the pathophysiology remains unclear, accumulating evidence points to the presence of low level immune activation both in the gut and systemically. Circulating polyunsaturated fatty acids (PUFAs) have recently attracted attention as being altered in a variety of disease states. Arachidonic acid (AA), in particular, has been implicated in the development of a proinflammatory profile in a number of immune-related disorders. AA is the precursor of a number of important immunomodulatory eicosanoids including prostaglandin E2 (PGE2) and leukotriene B4 (LTB4). Here, we investigated the hypothesis that elevated plasma AA concentrations in plasma contribute to the proposed proinflammatory profile in IBS. Plasma AA and related PUFAs were quantified by gas chromatography analysis in IBS patients and controls. Both PGE2 and LTB4 were measured in serum using commercially available ELISA assays. AA concentrations were elevated in our patient cohort compared to healthy controls. Moreover, we demonstrated that this disturbance in plasma AA concentrations leads to downstream elevations in eicosanoids. Together, our data identifies a novel pro-inflammatory mechanism in IBS and also suggests that elevated AA levels in plasma may serve as putative biological markers in this condition.

PMID: 19965606 [PubMed - as supplied by publisher]

View the full article
1 - 1 of 1 Posts
This is an older thread, you may not receive a response, and could be reviving an old thread. Please consider creating a new thread.